Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | MEDI5395 |
| Synonyms | |
| Therapy Description |
MEDI5395 is an oncolytic virus that expresses GM-CSF, potentially resulting in enhanced antitumor immune response (Cancer Res July 1 2017 (77) (13 Supplement) 4556, PMID: 32088771). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| MEDI5395 | recNDV-GM-CSF|MEDI 5395|MEDI-5395 | MEDI5395 is an oncolytic virus that expresses GM-CSF, potentially resulting in enhanced antitumor immune response (Cancer Res July 1 2017 (77) (13 Supplement) 4556, PMID: 32088771). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT03889275 | Phase I | Durvalumab Durvalumab + MEDI5395 MEDI5395 | A Study of MEDI5395 in Combination With Durvalumab in Subjects With Select Advanced Solid Tumors | Completed | USA | GBR | 0 |